Trials / Completed
CompletedNCT01278940
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PRIMARY OBJECTIVES: Determination of safety and toxicity of vaccination with patients' tumour mRNA transfected DCs . SECONDARY OBJECTIVES:Determine immunological response to the vaccine (induction of specific T-cell response) and assessment of tumour response
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dendritic Cells (DC) malignant melanoma | The patients were assigned to intradermal or intranodal DC vaccination |
| PROCEDURE | IL-2 | IL-2 were administrated by intranodal injection |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2006-02-01
- Completion
- 2015-12-01
- First posted
- 2011-01-19
- Last updated
- 2016-08-15
Source: ClinicalTrials.gov record NCT01278940. Inclusion in this directory is not an endorsement.